BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Serpik, V [1 ]
Protsenko, M. [1 ]
机构：
[1] Sechenov Univ, Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY13
引用
收藏
页码：S903 / S903
页数：1
相关论文
共 50 条
  • [31] BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY
    Wu, C. Y.
    Wang, Q.
    Shi, J.
    Zhang, X.
    Du, R.
    Gu, J.
    Liu, Q. H.
    Yu, J.
    Xu, J. W.
    Zhang, Y. J.
    Zhu, H.
    Li, M.
    Zeng, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1418 - 1418
  • [32] BUDGET IMPACT OF BARICITINIB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH AN INADEQUATE RESPONSE TO TOPICAL TREATMENTS
    Fenske, C.
    Rosettie, K.
    Ferrufino, C.
    Borns, M.
    Atiya, B.
    Johnson, N.
    Wehler, E.
    VALUE IN HEALTH, 2021, 24 : S229 - S229
  • [33] BUDGET IMPACT ANALYSIS OF FORMOTEROL EASYHALER IN THE TREATMENT OF ASTHMA IN CHILDREN IN THE RUSSIAN FEDERATION
    Kulikov, A.
    Kilimanova, E.
    VALUE IN HEALTH, 2015, 18 (07) : A497 - A497
  • [34] TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    de Lartigue, J.
    DRUGS OF TODAY, 2012, 48 (08) : 533 - 543
  • [35] BUDGET IMPACT ANALYSIS OF INTRODUCING TOFACITINIB FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN HONG KONG
    Li, X.
    Chan, E. W.
    Wong, I. C.
    VALUE IN HEALTH, 2018, 21 : S80 - S80
  • [36] Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
    Chen, Ying-Chou
    Yoo, Dae Hyun
    Lee, Chang Keun
    Li, Ko-Jen
    Won, Ji-Eon
    Wu, Wen-Shuo
    Zhong, Jinglin
    Nicolay, Claudia
    Walls, Chad Daniel
    Tanaka, Yoshiya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (01) : 65 - 73
  • [37] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
    Odnopozova, Liudmila
    Edin, Anton
    Sukharev, Alexey
    Wu, Tianshuang
    Aydin, Kerstin
    Kelly, Maureen
    Khotko, Alkes
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2063 - 2075
  • [38] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
    Liudmila Odnopozova
    Anton Edin
    Alexey Sukharev
    Tianshuang Wu
    Kerstin Aydin
    Maureen Kelly
    Alkes Khotko
    Dermatology and Therapy, 2022, 12 : 2063 - 2075
  • [39] COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Maniadakis, N.
    Boumpas, D.
    Kourlaba, G.
    Christou, P.
    Anargiros, I
    Smets, E.
    Purcaru, O.
    VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [40] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    RHEUMATOLOGY, 2021, 60 (05) : 2256 - 2266
12345